Previous close | 41.10 |
Open | 40.60 |
Bid | 55.40 |
Ask | 58.50 |
Strike | 260.00 |
Expiry date | 2025-01-17 |
Day's range | 39.41 - 41.10 |
Contract range | N/A |
Volume | |
Open interest | 283 |
Two of Biogen's newest drugs walloped first-quarter sales expectations on Wednesday, and helped Biogen stock jump.
Biogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key drugs like Tecfidera, Tysabri & Spinraza declined, the company's cost-saving efforts show promise.